Aduro BioTech Inc (ADRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Aduro BioTech Inc (ADRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH36915D
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that focuses on the discovery, development and commercialization of therapies for the treatment of cancer. The company develops its product candidates using its proprietary technology platforms such as live, attenuated, double-deleted (LADD) listeria mononcytogenes; cyclic dinucleotides; and B-select antibodies to treat a variety of cancers. Its products under development are intended for the treatment of multiple indications, including pancreatic, lung, ovarian, and prostate cancers, mesothelioma and glioblastoma. The company has collaboration with various pharmaceutical companies, to expand its products and technology platforms. Aduro BioTech is headquartered in Berkeley, California, the US.

Aduro BioTech Inc (ADRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13

Venture Financing 15

Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15

Aduro BioTech Raises USD55 Million in Series C Financing 16

Aduro BioTech Raises US$7 Million In Venture Financing 17

Aduro BioTech Raises US$6.5 Million In Venture Financing 18

Aduro BioTech Secures US$0.5 Million In Venture Financing 18

Aduro BioTech Secures US$19.25 Million In Series B Financing 19

Partnerships 20

Aduro BioTech Enters into Agreement with Merck 20

University of California, Berkeley Enters into Agreement with Aduro Biotech 20

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 21

Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 22

Licensing Agreements 24

Aduro BioTech Enters into Licensing Agreement with Stanford University 24

Aduro BioTech Enters into Licensing Agreement with UCB 24

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 26

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 26

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 28

Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 29

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 30

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 31

Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 32

BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 33

Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University 34

Equity Offering 35

Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 35

Aduro BioTech Raises USD25 Million in Private Placement Shares 36

Aduro BioTech Raises USD136.8 Million in IPO 37

Acquisition 38

Aduro Biotech to Acquire BioNovion 38

Consegna Group Completes Acquisition Of Aspen Medisys 39

Aduro BioTech Inc-Key Competitors 41

Key Employees 42

Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Recent Developments 44

Financial Announcements 44

Mar 01, 2017: Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results 44

Nov 02, 2016: Aduro Biotech Reports Third Quarter 2016 Financial Results 46

Aug 03, 2016: Aduro Biotech Reports Second Quarter 2016 Financial Results 47

May 02, 2016: Aduro Biotech Announces First Quarter 2016 Financial Results 48

Mar 08, 2016: Aduro Biotech Announces Fourth Quarter and Full Year 2015 Financial Results 49

Corporate Communications 50

Sep 06, 2016: Aduro Biotech Appoints Oncology Expert and Industry Veteran Natalie Sacks, M.D. as Chief Medical Officer 50

Product News 51

03/24/2016: Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer 51

Product Approvals 52

Nov 21, 2016: Partial Clinical Hold Lifted and Enrollment Resumes for Aduro Biotech LADD Clinical Trials 52

Clinical Trials 53

Dec 03, 2016: Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma 53

Nov 12, 2016: Aduro Biotech Highlights Positive Clinical Results from Second Cohort of Phase 1b Mesothelioma Clinical Trial 54

Sep 27, 2016: Aduro Biotech Presents Encouraging Preclinical Data Showing on listeria-based immunotherapy construct 56

Sep 27, 2016: Aduro Biotech Presents Encouraging Preclinical Data Showing on Stimulator of Interferon Genes 57

Jun 04, 2016: Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO 58

May 16, 2016: Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint in Heavily Pretreated Metastatic Pancreatic Cancer 59

May 12, 2016: Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors 60

Apr 28, 2016: Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma 61

Apr 11, 2016: Aduro Biotech Chief Scientific Officer to Highlight the Potential of STING Activation in Cancer Immunotherapy in a Major Symposium at the 2016 American Association for Cancer Research Annual Meeting 62

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63

List of Figures

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Aduro BioTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Aduro BioTech Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Aduro BioTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13

Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15

Aduro BioTech Raises USD55 Million in Series C Financing 16

Aduro BioTech Raises US$7 Million In Venture Financing 17

Aduro BioTech Raises US$6.5 Million In Venture Financing 18

Aduro BioTech Secures US$0.5 Million In Venture Financing 18

Aduro BioTech Secures US$19.25 Million In Series B Financing 19

Aduro BioTech Enters into Agreement with Merck 20

University of California, Berkeley Enters into Agreement with Aduro Biotech 20

Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 21

Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 22

Aduro BioTech Enters into Licensing Agreement with Stanford University 24

Aduro BioTech Enters into Licensing Agreement with UCB 24

Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 26

Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 26

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 28

Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 29

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 30

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 31

Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 32

BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 33

Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University 34

Aduro Biotech to Raise up to USD100 Million in Public Offering of Shares 35

Aduro BioTech Raises USD25 Million in Private Placement Shares 36

Aduro BioTech Raises USD136.8 Million in IPO 37

Aduro Biotech to Acquire BioNovion 38

Consegna Group Completes Acquisition Of Aspen Medisys 39

Aduro BioTech Inc, Key Competitors 41

Aduro BioTech Inc, Key Employees 42

Aduro BioTech Inc, Other Locations 43

Aduro BioTech Inc, Subsidiaries 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16065
Site License
USD 500 INR 32130
Corporate User License
USD 750 INR 48195

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com